Balyasny Asset Management
VIVO

Balyasny Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Balyasny Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,357
Closed -$244K – 3415
2022
Q4 		$244K Buy
+7,357
New +$237K ﹤0.01% 2062
2021
Q4 		– Sell
-140,148
Closed -$2.7M – 2714
2021
Q3 		$2.7M Buy
140,148
+124,715
+808% +$2.49M 0.01% 1030
2021
Q2 		$342K Buy
+15,433
New +$327K ﹤0.01% 1628
2020
Q3 		– Sell
-253,273
Closed -$5.9M – 1681
2020
Q2 		$5.9M Buy
253,273
+52,686
+26% +$764K 0.05% 476
2020
Q1 		$1.69M Buy
+200,587
New +$1.69M 0.02% 648
2016
Q4 		– Sell
-20,373
Closed -$393K – 1524
2016
Q3 		$393K Sell
20,373
-6,000
-23% -$117K ﹤0.01% 778
2016
Q2 		$514K Sell
26,373
-4,985
-16% -$97.8K ﹤0.01% 820
2016
Q1 		$646K Buy
31,358
+15,700
+100% +$309K ﹤0.01% 836
2015
Q4 		$321K Buy
+15,658
New +$300K ﹤0.01% 952

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's VIVO Position: Q1 2023 in Review

Balyasny Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 7,357 shares — an estimated $244K sold.

Balyasny Asset Management first reported a position in VIVO in Q4 2015 and held it in 9 quarters. The position peaked at $5.9M in Q2 2020. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Balyasny Asset Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 7,357 Meridian Bioscience Inc shares in Q1 2023, an estimated $244K.
  • Balyasny Asset Management first reported a position in Meridian Bioscience Inc in Q4 2015 and held it in 9 quarters.
  • Balyasny Asset Management's Meridian Bioscience Inc position peaked at $5.9M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.